Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
Stocks in this Quantisnow insightHealth Care
Historical context for JNJ
Across the 22 sessions after earlier JNJ headlines, the stock closed higher 12 times and lower 10 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | JNJ | SPY |
|---|---|---|---|
| Sep 3, 2026 | Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit | +1.2% | +1.0% |
| Sep 2, 2026 | UBS resumed coverage on Johnson & Johnson with a new price target | +1.5% | +0.4% |
| Sep 1, 2026 | Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results | +2.0% | -0.7% |
| Aug 25, 2026 | FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients | +0.0% | +0.3% |
| Aug 11, 2026 | Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | -0.8% | -0.3% |
| Aug 5, 2026 | Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference | +1.0% | -0.2% |
Quantisnow market dataNYSE
JNJ
Johnson & Johnson
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for JNJ
Full JNJ profile on Quantisnow Follow JNJ and get a push notification the moment its next story breaks.